157 related articles for article (PubMed ID: 34519192)
21. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
22. Continuation of Renin-Angiotensin-Aldosterone Inhibitors Does Not Impact Renal Function Among Patients Undergoing Percutaneous Nephrolithotomy.
Patel N; Cohen BR; De S; Kartha G; Li I; Sarkissian C; Calle J; Monga M
J Endourol; 2017 Jun; 31(6):577-582. PubMed ID: 28340535
[TBL] [Abstract][Full Text] [Related]
23. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
[TBL] [Abstract][Full Text] [Related]
25. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR).
Kim KH; Choi BG; Rha SW; Choi CU; Jeong MH;
BMC Cardiovasc Disord; 2021 May; 21(1):251. PubMed ID: 34020593
[TBL] [Abstract][Full Text] [Related]
26. Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
Martínez-Milla J; García MC; Urquía MT; Castillo ML; Arbiol AD; Monteagudo ALR; Mariscal MLM; Figuero SB; Franco-Pelaéz JA; Tuñón J
Drugs Aging; 2019 Dec; 36(12):1123-1131. PubMed ID: 31493202
[TBL] [Abstract][Full Text] [Related]
27. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of renin-angiotensin blockade in atherosclerotic renal artery stenosis.
Sofroniadou S; Kassimatis T; Srirajaskanthan R; Reidy J; Goldsmith D
Int Urol Nephrol; 2012 Oct; 44(5):1451-9. PubMed ID: 22127407
[TBL] [Abstract][Full Text] [Related]
29. Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients.
Farid Fahmy S; El Derany MO; Khorshid H; Saleh A; El-Demerdash E
BMC Pharmacol Toxicol; 2023 Apr; 24(1):24. PubMed ID: 37060024
[TBL] [Abstract][Full Text] [Related]
30. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
[TBL] [Abstract][Full Text] [Related]
31. Renin-Angiotensin-Aldosterone System Optimization for Acute Decompensated Heart Failure Patients (ROAD-HF): Rationale and Design.
Dass B; Dimza M; Singhania G; Schwartz C; George J; Bhatt A; Radhakrishnan N; Bansari A; Bozorgmehri S; Mohandas R
Am J Cardiovasc Drugs; 2020 Aug; 20(4):373-380. PubMed ID: 31797310
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Kim HS; Kim H; Lee SH; Kim JH
J Clin Pharm Ther; 2020 Dec; 45(6):1264-1270. PubMed ID: 32737930
[TBL] [Abstract][Full Text] [Related]
33. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
34. The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
Alashkham A; Paterson C; Windsor P; Struthers A; Rauchhaus P; Nabi G
Clin Genitourin Cancer; 2016 Oct; 14(5):398-405. PubMed ID: 27053500
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
Zhang L; Zeng X; Fu P; Wu HM
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
[TBL] [Abstract][Full Text] [Related]
38. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
39. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
[TBL] [Abstract][Full Text] [Related]
40. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
